Skip to content
Telehealth Graded
State guide

North Dakota Medicaid and GLP-1s

The takeaway

North Dakota Medicaid requires six months of semaglutide in a weight program before tirzepatide for sleep apnea, and an Ozempic escalation before Wegovy.

Reading the state documents

North Dakota does not just set criteria, it sets an order. The sleep-apnea route to tirzepatide requires six months of documented pharmacotherapy with semaglutide first, and if that is not tolerated, phentermine. The cardiovascular route to Wegovy requires escalating to 2 mg of Ozempic first. Meanwhile four older obesity drugs are covered with no prior authorization at all, on a diagnosis code alone.

1
document cited
9
sourced facts
1
primary source

What changed, and what the document says

  1. Four obesity drugs, no authorization

    Covered

    The old oral agents are covered on a diagnosis code, with nothing else asked.

    “The following drugs are covered without prior authorization by submitting a corresponding”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  2. And they are named

    Covered

    A short, specific list — no GLP-1 appears on it.

    “phentermine, bupropion, naltrexone, topiramate”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  3. Six months of semaglutide before tirzepatide

    Conditions apply

    This is the requirement that makes North Dakota different. The cheaper drug has to be tried first, and for half a year.

    “The member must have documentation of participation in a comprehensive weight”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  4. The program, spelled out

    Conditions apply

    Behavior, diet, activity and a drug, all four, for at least six months.

    “physical activity, and pharmacotherapy for at least 6 months with semaglutide.”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  5. An Ozempic escalation before Wegovy

    Conditions apply

    The same logic on the cardiovascular side: the diabetes product has to be tolerated at full dose before the obesity-labeled one is authorized.

    “If the member qualifies for Wegovy injection, a dose escalation to 2mg of Ozempic injection”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  6. A year on injections before tablets

    Conditions apply

    The oral form is treated as the last resort, not the convenient one.

    “Wegovy tablets: The member must have failed a 12-month trial of semaglutide injection, as”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  7. Six months of CPAP first

    Conditions apply

    The sleep-apnea route also requires the machine to have been tried and failed, with a fresh index to prove it.

    “The member must have failed a 6-month trial of continuous positive airway pressure (CPAP)”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  8. Cost decides which tirzepatide

    Context

    Where more than one product would qualify, the state names price as the tiebreaker in writing.

    “If the member qualifies for tirzepatide, the most cost-effective tirzepatide product will be”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

  9. Diabetes disqualifies you from this route

    Conditions apply

    The sleep-apnea pathway is closed to people with type 2 diabetes, who are routed to the diabetes criteria instead.

    “The member does not have diabetes type II”

    Medical Services Division, North Dakota Department of Health and Human Services — Version 2026.6, Effective: July 31, 2026

Telehealth in North Dakota

  • CCaveat
    $1,299
    a month, medication only
    brand Ozempic (semaglutide), cash price
    Additional fees not verified.
    Price details
    • No separate monthly fee was found in the pages reviewed. Other charges may apply.
    • Brand-name Ozempic, quoted as a cash price. Gala says insurance may reduce it and does not publish what it would reduce it to.
    See Gala Health pricing (opens in a new tab)
  • HumeCare+Partner
    CCaveat
    $249Signup price
    a month, medication only
    compounded semaglutide, six-month plan
    Additional fees not verified.
    Price details
    • No separate monthly fee was found in the pages reviewed. Other charges may apply.
    • $179 the first month, $249 a month after; the checkout totals the six months at $1,424. The card shows the later price only once the plan is selected.
    • Price shown after 40 signup steps.
    See HumeCare+ pricing (opens in a new tab)

Some providers pay us a commission when you sign up through our links, at no extra cost to you.

Which of these companies serve North Dakota?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

18 of those lists name North Dakota: Gala Health, Care Bare Rx, Vita Bella, TelePeptide, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Trimi, HumeCare+, Rx.com, Mojoon, Peak Wellness, Allara Health, MEDvidi, and Mixx Health & Wellness. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.

Sources

Source dates below are the dates printed on the documents.

Nothing on this page is medical advice, and nobody here is a clinician. Coverage rules change; check the linked document before you rely on it.